Characteristic | DS (n = 15) | CR (n = 16) |
---|---|---|
Median age [yr] (range) | 48 (16–65) | 68 (25–83) |
Male (%) | 9 (60) | 8 (50) |
Brucellosis risk factor | Â | Â |
   Occupational exposure (%) | 1 (6.7) | 8 (44.4) |
   Ingestion of unpasteurized dairy products (%) | 14 (93.3) | 14 (87.5) |
Duration of symptoms before therapy (weeks) | Â | Â |
   Mean ± SD | 14.9 ± 13.0 | 15.3 ± 12.0 |
   Median (range) | 12 (2–40) | 14 (2–48) |
Operation before therapy n (%) | 0 | 5 (31) |
Symptoms | n (%) | n (%) |
Malaise | 12 (80) | 15 (94) |
Back pain | 14 (93) | 14 (88) |
Arthralgia | 13 (87) | 14 (88) |
Sweating | 11 (73) | 15 (94) |
Anorexia | 7 (47) | 15 (89) |
Fever | 9 (60) | 11 (69) |
Myalgia | 9 (60) | 11 (69) |
Nausea | 4 (27) | 5 (31) |
Abdominal pain | 2 (13) | 5 (31) |
Vomiting | 2 (13) | 2 (13) |
Findings | Â | Â |
   Fever | 1 | 3 |
   Hepatomegaly | 2 | 1 |
   Splenomegaly | 0 | 1 |
   Laseque test positivity | 5 | 8 |
Clinical spectrums (duration of symptoms) | Â | Â |
   Acute (<8 weeks) | 6 | 5 |
   Subacute (8–52 weeks) | 9 | 10 |
Chronic (>52 weeks) | 0 | 1 |
Patients hospitalised | 3 | 6 |
Laboratory findings of 31 patients at baseline in the two groups | ||
Laboratory finding | DS (n = 15) (%) | CR (n = 16) (%) |
Anemia | 4 (27) | 7 (44) |
Leucocytosis | 0 | 2 (13) |
Median ESR | 22 (3–110) | 54 (2–88) |
Median CRP | Â | Â |
Before therapy | 33 (3–151) | 53 (3–140) |
After therapy | 3 (3–5) | 5 (3–14) |
Median agglutination titer (range) | 320 (160–2560) | 320 (160–1280) |
Positive blood culture (%) | 0 | 4 (22) |